biosimilar drugs

Business Group Makes Price Recommendations for Specialty Drugs
Business Group Makes Price Recommendations for Specialty DrugsThe high cost of specialty drugs demands a change in Washington, according to a report.
How New Biosimilars Will Impact the MarketMore biosimilars are coming onto the market , including competitors for Remicade and Neulasta.
New diabetes medications help address linked diseasesExperts share updates on new diabetes medications, and provide an overview of what’s coming.
Are payers optimistic about biosimilars’ savings?As more biosimilars are approved, plans and PBMs will continue to evolve their strategies regarding coverage and formulary management of these new medications.
Breast cancer biosimilar shows equivalency to brand
Breast cancer biosimilar shows equivalency to brandTwo new major studies on a biosimilar to trastuzumab (Herceptin, Genentech) to treat HER2-positive metastatic breast cancer and HER2-positive gastric cancer demonstrated equivalency.
What executives must know to combat rising drug spendIn today’s healthcare landscape, few things better define the role of a managed healthcare executive than managing the industry’s constant changes.
FDA approves biosimilar to HumiraFDA’s pace of biosimilar approvals is picking up, as it approved two major drugs for rheumatoid arthritis and other inflammatory diseases in the past month.
Predictions for biosimilars: How market access will play outEarly planning to craft a comprehensive real-world evidence generation strategy can help support the real-world safety and effectiveness of biosimilars.
Can costs be contained?There’s a lot of blame to go around when it comes to why drug costs are rising in dermatology. We’ll let the research do the finger pointing.
Why pharmacists are concerned about the safety of biosimilarsPharmacists and other healthcare professionals are looking to the FDA for more guidance on biosimilars and interchangeability with their reference products.